untitled

ACS34_07高柳.indd

1. ICU 2002 2005 2006 32 ICU 1) 2) 3) 3 2. 2.1. 123 8 (1716 1735) ICU 1736 2 1 3 4) ICU 5) 2.2. a 1923 110 30 6) 1924 15 16 7) 8) ICU 1 1935 9) 1930 1 120 10) 1936 11) 12) 124 b 1917 1927 1922 13) 14)

,

8 8 0

,07,,08, 8 8 0 7 8 7 8 0 0 km 7 80. 78. 00 0 8 70 8 0 8 0 8 7 8 0 0 7 0 0 7 8 0 00 0 0 7 8 7 0 0 8 0 8 7 7 7 0 j 8 80 j 7 8 8 0 0 0 8 8 8 7 0 7 7 0 8 7 7 8 7 7 80 77 7 0 0 0 7 7 0 0 0 7 0 7 8 0 8 8 7

PISA

-1- -2- -3- -4- -5- -6- -7- -8- -9- -10- -11- -12- -13- -14- -15- -16- -17- 1. 2. 3. -18- -19- -20- : : : : -21- 3 # # # 25 17 51 13 41 12 25 3 10 23 10 5 30 66 15 8 5 3 88 144 284 67 50 37-22- -23- -24-

Digital Photo Professional Ver1.6（Windows）

Windows CT1-5193-000 CANON INC. 2005 J 1 2 3 4 s s s 1 1 s s s s s 1 1 a s s 1 s s 1 2 s a 1 s a 2 3 1 1 s a a 2 a 3 a s s 1 a a s a s s 1 s s 1 2 3 s 1 1 a 2 a 1 a s 2 3 1 1 s a 2 1 3 1 s a 2

講座の記録

救急車同乗実習レポート　総括

14 9 1 9 10 10 19:00 23:00 52 1 6.5 40 CT X CT Ope 15 /min BP 100/70mmHg HR 96 /min O U m 60 25/min BP 140/80mmHg HR 55 O Spo 98 BP 172/68mmHg O 30 15 /min BP 100/60mmHg HR 80 /min BS O O CO 30 40 JCS

! ! ! a b SIMV 12/min 0 (cmh 2O) 500.0 P/F (cmh 20) 8 0 (cmh 20) 6 400.0 300.0 200.0 100.0 (cmh 2O) 200 180 160 140 120 100 80 60 40 20 0 PS in 2043 2257 2115 2723 3022 3400

発達障害_表01

ICU ( ) ICU ( ) ICU SpO 2 ICU ( ) -297 S.E DEX: N=30 DEX: N= 6 (J-DEX Placebo: N=30 Placebo: N= 3 65 DEX: N=16 DEX: N= 3 Placebo: N=

ICU ( ICU ( ICU SpO 2 ICU ( -297 S.E. -75-94 65 DEX: N=30 DEX: N= 6 ( Placebo: N=30 Placebo: N= 3 65 DEX: N=16 DEX: N= 3 Placebo: N=19 Placebo: N= 4 65 DEX: N=53 DEX: N=42 DEX: N=21 DEX: N=10 ( Placebo:

104 100 60 9,195,336 409 0.004 24 8 31 9,025,983 568 0.006 2012 8 31 6,634,686 956 ( 0.014 ) 2 2011 8 26

25 25 3 5 MMR 1 104 100 60 9,195,336 409 0.004 24 8 31 9,025,983 568 0.006 2012 8 31 6,634,686 956 ( 0.014 ) 2 2011 8 26 2012 8 31 1,032,660 132 ( 0.013 ) 3 2010 6 11 3 11 15.4 1 1 ( ) 12 2 2 3 ER ) (

2

1 2 17 1884 2 131 1 1..He lived to serve 2 2 2 2 14,416 104,000 1 QOL Quality of Life 2 21 2013 25 21 3 4 5 QOL 6 QOL QOL 59 1 60 7 QOL QOL 8 2,774 2015 27 5 7 241 2015 27 5 8 12 2015 3 7 58 1,030 113

橡アロマセラピー症状別処方例.PDF

1 1 92 E 100ml 1 2 2 1 93 0.5m 10ml 100ml 1 2 3 2 52 0. l 2 4 3 27 3 1 1 3 3 4 5 3 2g 2 3 1 1 1 10ml 3 4 6 3 29 2 2 2 10ml 3 3 4 7 3 30 2 1 2 10ml 3 3 4 8 3 31 1 1 1 1 3 60 10 10 3 2 4 10ml A 2 3 61 20

1 FEV1.0 FEV1.0 30 80% NIH FEV1.0 50 80% FEV1.0 50% FEV1.0 cyanosis PaO2 PaCO2 PaO2 PaCO2 40mmHg FEV1.0 25% 2 1 1 2

15 1 12 1 2 2 2 2.1.............................. 3 2.2........................... 3 2.3 β........................ 6 2.4............................ 7 3 8 3.1....................... 8 3.2....................

岐阜大学医学部・付属病院の現状と課題

1 21 2 100 6 16 35 5 5 MEDC 13 3 5 35 5 35 1 4 6 2 7 1 3 9 4 6 5 7 4 21 21 5 5 MEDC MEDC 13 2 12 5 17 1 1 96 16 7 62 5 3 8 8 10 21 50 3 1 ICU HCU CCU ICU 1 2 3 1 1 MINCUS 1 ICU 2 3 ICU HCU CCU 3 4 9 4

「東日本大震災に係る対応―保険診療・地域医療再生基金・災害復旧費補助金・医療法等について（第1報）」について

2012 3 28 2011 3 1 1 2012 3 2012 3 28 2012 3 28 2012 3 28 2012 3 28 1. 1 3 11 1 2 3 15 17 3 4 5 1 2012 3 28 5 10 6 3 18 7 5 8 3 23 9 2 2012 3 28 2011 3 23 23 10 3 2012 3 28 4 2012 3 28 5 2012 3 28 3 24

1

ICU/…A…WŁ¶32/10“‡Œö

V 1. 2002 1) 2) 12 2. 60 1941 12 1944 ICU B29 87 115 105 Z 54 1944 87 44 45 177 1945 4 21 22 8 3) 3. 1941 11 1 30 1944 2 1944 1 1941 8 4) 4. 5) 6) 5 1 50 7) 1944 4 1945 3 5 8) 4 3 160 1944 5 1945 3 3 3

ph

14 12 9 3 4 1 7 1.1..................... 7 1.2 ph............................ 9 1.2.1...... 9 1.2.2.... 12 4.4..... 55 1.2.3 14 4.4.1......... 56 1.2.4............. 19 2 21 2.1.......... 21 2.2......................

SpO2 FIO2 Hypoxic Pulmonary Vasoconstriction HPV 30 FIO2 FIO2 PaCO mL/kg I/E CPAP P

11 a. 2012 1 15 26 http://www1.koalanet.ne.jp/anesth_memorandum/sub19.html SpO2 FIO2 Hypoxic Pulmonary Vasoconstriction HPV 30 FIO2 FIO2 PaCO2 20 30 8 10mL/kg I/E CPAP PEEP 27 b. CO2 ( ) SpO2 COPD PETCO2

untitled

........ ,..,..,..,,..,..,.. ,. , OECD ............ / :........................ :........ ... .. OECD OECD....... OECD Health Data ,, , :..... JR.... ,.. t-pa NICU ICU ICU.... NICU NICU NICU NICU.....

untitled

2009116 HP 4 50 50 1 2 20032 3 1001 5 255 AASM AASM AHI 4 PaCo2 PaCo2 PaCo2 PaCo2 PaCo2 PaCo2 PaCo2 COPD PaCo2 PaCo2 COPD (%) 100 80 60 40 20 0 () 100 75 1 50 25 45 65 0 25 50 75 () Fletcher, C. et al:bmj

‡æ‡©…l…b…gŒ{Ł¶58

12 10 21 12 13 13 14 1 1987.11 1982 1984 10 180 1989 No.11993 1982S57 1984S5910 1987S62 1987S6211 1989H 1990H 1991H 1991H 1992H 1993H No 1993H 10 1994H 1995 H 1996H 1997H24 1998H1023 1999H1122 2000H1227

HR-ST700

HR-ST00 MULTI BRAND RCU 3 5 3 5 6 0 8 9 0/ OK/ LPT08-00B 0 50 5 59 6 38 3 8 5 6 3 33 3 8 9 50 5 5 53 5 55 56 58 59 6 63 6 38 0 3 5, 6 66 6 0 5 3 AC00V 5 6 3 5 6 8 9 0! @#$% ^ 38 3 3950 5 6 6 36 8 5 9

S22 vol. 38 Suppl. 2013 38-3-2 38-3-3 38-3-4 38-3-5 JA 4 6 15 14:35 15:15 3 38-4-1 1 JA 38-4-2 10 38-4-3 38-4-4 5 5 6 15 15:20 16:10 3 38-5-1 1 38-5-2

vol. 38 Suppl. 2013 S21 1 6 15 11:25 12:15 4 38-1-1 38-1-2 US 38-1-3 1 38-1-4 38-1-5 2 6 15 13:40 14:30 3 38-2-1 1 38-2-2 38-2-3 CHI-Q 38-2-4 1 38-2-5 IgG4 3 6 15 13:40 14:30 4 38-3-1 S22 vol. 38 Suppl.

医療レーザー脱毛の威力と限界

.... mm. CT WH W H W H W H... kcalkcal. 1. cal kcal 1 6 2 3. 4. 5. 1 6 6. B6 B12 B. BMI BMI30 C. D. kg mm . CT WH W H W H W H... kcalkcal . 1. cal kcal 1 6 2 3. 4. 5. 1 6 6. B6 B12 B. BMI BMI30 C. D.

HR-VT700

HR-VT00 MULTI BRAND RCU 3 5 3 5 6 0 8 9 0/ OK/ LPT09-00B 9 6 8 5 58 63 6 9 5 3 8 5 6 8 9 3 5 35 3 38 6 8 9, 50 5 5 53 5 55 56 5 58 59 60 6 63 66 68 5 8 9 80 8 83 3 AC00V 5 6 3 5 6 8 9 0! @#$% ^ 3 8 385

21 USDA 2006 USDA 06 0607

21 USDA 2006 USDA 06 0607 05 10 6,200 45 0631 202575 02 10 E-10 90 MTBE 90 MTBE 02MTBE 05 25MTBE 06 MTBE 06 25 01 05 201275 3.8 05 1,387 70 2104 0520.9 40 RFA 0610133 07 69 06 011,79005 4,060227 RFA2012

特許権侵害に対する損害賠償額の算定に関する裁判例の動向

[*361] 1998 1999 102 1 105 3 102 3 102 1 102 2 102 3 1. 2. 102 1 2.1 2.2 2.3 2.4 3. 102 2 3.1 3.2 4. 102 3 5. 1. 1) 102 1990 3 1 102 1 10 102 2 102 2 10 102 3 [*362] 2) 1998 1999 102 1 105 3 102 3 2 3)

2015 3 1.... 1 2.... 2 (1)... 2... 2... 3... 4 (2)... 5... 5... 6 (3)... 7 DPC... 7... 8 3.... 11 (1)... 11... 11... 12... 14 (2)... 15... 15... 16 (3)... 17... 17... 17 4.... 19 (1)... 19 (2) SWOT...

「学生とシニア」の対話実施報告書

in 2009.11.30 1. 2005 6 38 3 2 2. 3 3. 1 21 11 7 9301630 11 6 18302030 2 1 1 3 4 (90 )(50 )(75 ) 4. 5.(70 ) 6. 5 2 G1 (CO2 ) G2 () G3 () G4 (-) G5 () 5 2 10 1 CO2 Q&A 1 7. 3 2 3 9%, 62%, 27%, 2% 71% 23%,

評価結果報告書の概要版（平成20年度）

10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76

() CT X X Ver.5 64 ( 3.0 % / 24,, 25 H23 1 Dr 24 24 2 1 25 RI RI ICU 24 25 B 4500 13000 AHA-PALS 5 PALS 24 25 24 25 24 ICU 24 25 24 1 VA VA 25 25 VA HD VA 20 150 () () 25 2 24 25 24 24 414 102 25

EF-S55-250mm f/4-5.6 IS II 使用説明書

肝臓病教室201207v2配布用.pptx

24 7 28 5 C C C C 11 1 vs 2 vs 1 0 1 600-1000mg 3-5/ 24,48 2448 12 1 1500-2250mg 6-9/ () 1 600-1000mg 3-5/ 0 24 88.1% 0 20 40 60 80 100 C ALT, GPT 30 34.4% ALT, GPT 0 20 40 60 80 100 2 , 2 3 1 1-100% 0

Stage 28 4 28 7 !! 15 EMB POMRProblem Oriented Medical Record SOAPSubjectiveObjectiveAssessmentPlan 1 2 ID 3 ID SOAP 4 5 6 ~ ~~~~~~~~~~~~~ Stage Stage 2 1. X CT 2. 1 30 60 3. 5. 4

本文01id5.indd

1 TFT 9F 906 907 907 1 TFT 9F 906 90 1 P1-01 P1-02 1 1 1 2 1 1 2 P1-03 P1-04 P1-05 4 P1-06 P1-07 P1-08 1 1 1 2 1 2 P1-09 VCM TDM VCM 1 2 2 2 3 3 4 5 1 2 3 4 5 2 P2-01 P2-02 P2-03 83 1 TFT 9F 906 907 906

1 5 6 2 3 7 8 4 5 9 10 6 7 11 12 8 1 2 3 4 5 6 7 1989 25.0% 19901999 6 2000 15.0% 9 13 1 2 3 4 5 50 2 5180 45.0% 81 35.0%, 5.0% + +, 5.0% +, 1, 5 +, 3 14 10 0% 20% 40% 60% 80% 100% n=20 3 5 2 n=20 55.0%

untitled

7 ( ). 1. 2. 3. 4. 5. 6. . 1. (C.difficile associated disease CDAD) 1) CDAD 60 72 2 CDAD Toxin CDAD 2) (1) C.difficile C.difficile (2) C.difficile (toxin A toxin B) toxin A toxin B (A+B+) toxin A toxin

04_ポスター.indb

般ポスター基礎超音波計測一般 一般ポスター基礎 6 月 8 日 ( 金 ):00 - :0 ポスター会場 ( 神戸ポートピアホテル B F 座長 : 9- 基 P-00 S790 9- 基 P-00 S790 9- 基 P-00 S79 Jing ZHU, 9- 基 P-00 S79 9- 基 P-005 S79 9- 基 P-006 CT S79 Wenjing WU 9- 基 P-007 HIFU

JPN-1

EF70-200mm f/2.8l IS II USM JPN JPN-1 a JPN-2 JPN-3 1. JPN-4 2. 3. JPN-5 4. JPN-6 5. JPN-7 6. JPN-8 7. JPN-9 JPN-10 8. 9. JPN-11 10. JPN-12 11. 12. 13. JPN-13 14. JPN-14 JPN-15 canon.jp/ef 050-555-90001

MP-E 65mm f/2.8 1-5× 使用説明書

MACRO PHOTO LENS MP-E 65mm f/2.8 1-5 JPN JPN-1 a JPN-2 JPN-3 1. 2. JPN-4 JPN-5 JPN-6 3. JPN-7 JPN-8 4. JPN-9 5. JPN-10 6. 7. JPN-11 8. JPN-12 canon.jp/ef 050-555-90001 JPN-13 CT1-7525-010 CANON INC. 2002

32 TEL: 0959-52-3000 FAX: 0959-52-4467 Email: nkh@orange.ocn.ne.jp URL: http://www.kamigoto-hospital.jp/ 1 73 MRI IT IVR PTCA 74 MC CT) NECMega-Ork 75 Web HTLV-IATL 2 ICU Holter MD-C T MRIX DSAFCR 3 4

2007 116 20 1 19 2 6 2 19 2 2007 4 2

http://www.shijuku.net 2007 116 20 1 19 2 6 2 19 2 2007 4 2 1/14 New Years Party 2007 In NEW YEAR PARTY 330 Wii 4 Wii ii 1/14 NEW YEAR PARTY 11 277-0852 1-6-5 04-7141-5101 04-7141-5106 www.sougakusya.com

: : BSC - - :

2013 : : BSC - - : - - 58 30 9 70 3 3 1 Association of genetic variants of the α kinase1 gene with myocardial infarction in community dwelling individuals Abstract. ALPK1 ALPK1

21 8 20 70 1 1 2 1 1 20 12 22 16201835 2 21 1 21 15001910 3 21 2 23 15001750 4 21 3 23 15002030 5 21 4 27 15102010 6 21 6 15 15002110 7 21 7 27 15001910 2 3 3 21 3 21 4 2 4 1 2 1 2 312 4 3 1 2 3 4 2

ACSS21_06梅津.indd

70 60 ICU ICU ICU ICU ICU 14 14 1970 25 ICU ICU 55 ICU ICU 2014 140 ICU 1952 8 7 23 5 1 7 5 10 22 Tokyo Anglo-Japanese Seminary The Methodist Mission Seminary ICU 56 6,000 ICU ICU ICU ICU Academy, College,

平成１５年度先進的情報技術活用モデルシステムの開発

2 3 IT SI (1) (2) (3) (4) 24 (1)(4) 61 FM CATV IT 500 320 8,000 16 12 4 1 5 CT NTT ADSL ()( MIL )(DICOM ) () MIL (Web) / Web 2 6 (Web)CT 3 7 ( ) 24 4 8 DICOM CT () 9 5 CMC() () () ()NTT-ME 10 ( ) () CT

untitled

11 10 267 6 129 48.3 6 63 2 1 2JIS ME JIS T 1005JIS 1994 1 11 A 10 1999 5 3 13 ME 4 2 11 B B 1999 4 10 267 6 B 7 9 6 10 12 3 11 Excel MODE Excel STANDARDIZE STANDARDIZE(X,)X AVERAGE STDEVP Excel VAR 0.5

カラーイメージランナー iRC5870/C5870N カタログ

LIPS LX LIPS LX PostScript3 LIPS LX LIPS V LIPS V PS Apple Talk PAP TCPIP SMB LPR IPP Port9100 PRODUCT OUTLINE PRODUCT OUTLINE Dummy ENGINE IMAGE CONTROL IMAGE CONTROL PAPER HANDLING PAPER HANDLING ENVIRONMENT

A 01 2 015 10 11 12 G 011 2 0111 67

66 A 01 2 015 10 11 12 G 011 2 0111 67 0119 0112 0113 68 0130 0128 0114 0113 0115 0116 0119 69 0111 0128 012 2 0121 1102 0122 0123 0124 70 0125 0126 0126 0111 0127 71 0128 0129 0230 013 0130 0130 011 012

10 35 10 1 1 5 1 2 3 2 1 34 37.000 28,000 75 203 208 655 7,000 8,000 655 7 70 7 10 1 1,700 5,500 2 7 2 3 9 34 3 4,100 9 1,800 1 1 34 5,800 4,200 470 280 3400 32 1 5 97.8 7 3 34 65 1 40 70 1 2 9 3 3 1 6

NIHSS score p NIHSS score p149 4 p g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml

NIHSS score14 1 400 1 p149 1 25 20 NIHSS score14 15 10 5 2 p149 4 p151 0 0.8 g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml 1 2 148 149 3 2 3 A B C 4 D 2 A B C A C 1 Ogata T et al J Neurol Sci 272 83 86 2008

- 1 - - 2 - - 3 - - 4 - - 5 - - 6 - 20log10 150 = 44 20log10 150 = 44-7 - - 8 - - 9 - - 10 - L ks X n + X 2 2 ) ( 1) ( 1 = X X n S n n n X L k k n X n X S n L n k - 11 - - 12 - - 13 - - 14 - - 15 - - 16

PSCHG000.PS

FA X SA RS W H O DM AT ACLS TR BCG BCG GDP GDP JO A JC O A ATL W H O GNP OB g ICLS IC L S AED IC L S AED AED Dr. a ODA b c d d d d ddic d c VT VT VT VT VT VT VT VT VT VT VT VT c

untitled

面付 北斗No16本文

1619310 27202724 920-0293 1-1 TEL076286-2211 FAX076286-8214 25 80 30 17 9 10 10 1 10 1 1015 1022 1023 1026 1029 1029 1030 11 2 11 9 1113 1115 1119 1120 1121 1126 1127 1127 1130 1210 1226 20 342 302 33

untitled

1 ( ) ( ) QMS-H ( ) ( ) 27 ( ) ( ) GK SHIAN CREATIVE PARTNERS 28 2 ( ) () NTT ( ) () ( ) 29 3 () 15-1 A 1) 1) 1) 1) 1) 2) 3) 4) 1) 2) 3) 4) 15-2 15-3 1) 2) 3) 4) 1) 2) 3) 4) 15-4 ( ) 16-1 16-2 1) 2) 1)

untitled

59 2014 712 59 2014 712 59 171 3F 2F 1F B2F B3F B2F 900 1 2 3 900930 900 1630 30940 1000 1100 9401140 9401050 1 D11 D17 10501200 3 9 D31 D37 9401050 2 10501200 D21 D27 4 D41 D47 1200 1300 12101310 1 12101310

がん診療におけるFDG FDG-PET/CTの役割

PET/CT PET/CT MRI PET PET/CT Kurashiki Central Hospital FDG-PET CT PET/CT (stage1) FDG-PET (stage1) PET/CT FDG-PET PET/CT (stage4) FDG-PET (stage4) PET/CT FDG-PET PET/CT PET/CT

program.pdf

- - FAX E-mailjsnr-office@umin.ac.jp http://jsnr.umin.jp/ Cheryle Tatano Beck Vol. No. ,,, PC Vol. No. USBCD-ROM PC PCOS Windows XPPowerPointMS MSMSP PC Vol. No. , Vol. No. Vol. No. 会場までの交通機関 日本看護研究学会雑誌

平成１８年度厚生労働科学研究費補助金

19 3 19 3 目次 1 要旨 1 2 本文 第 Ⅰ 部 在宅医療計画の主旨 Ⅰ-1 在宅医療とは 3 Ⅰ-2 在宅医療計画の背景 : 国民のニーズと医療提供実態のミスマッチ 3 Ⅰ-3 医療計画における在宅医療の位置づけ 12 Ⅰ-4 在宅医療機関及び各連携機関とは 14 Ⅰ-5 在宅医療計画の展開 32 Ⅰ-6 医療費適正化計画 介護保険計画との整合性について 34 第 Ⅱ 部 利用者の視点に立った在宅医療計画の概要

CT_08-01.ai

2009-12 CT55DD 80,000 CTF55B 8,000 CTF55D 3,200 41m 2 BIO HEPA ECO 5 21 20m 2 1210 4.3 1,542 http://www.kuusei.jp/ https://ssl.mhiair.co.jp/app/ contact/?form_number=3 https://ssl.mhiair.co.jp/shop/

untitled

1 ... 3... 3... 3... 4...13...16...18...20...22 2 PTPE 3 PTPE CT Grade 2 A PTPE PTPE 4 A S 3 3 B H3,P1,N1,M1, LM0, R23 15 20gS, ptype 3, 60 x 50mm, pt4b/siurinary bladder, int, INF, ly2, v1, ppm070mm,

原発緊急講演

2011 3 11 2 46 9.0 2011 2 22 11,000 1995 1 17 7.3 350 1923 9 1 45 tsunami 1 6 1 3 4 6 1 3 1,3 2 1 Bq 1 PBq 1000 85 10.7 22PBq 90 28.8 190PBq 95 64 5900PBq 106 372 700PBq 131 8 3100PBq 133 5.24 6300PBq

第1回日本産婦人科

e e TEL045-231-0960 TEL03-3433-1111 3360 4 2 1 1024768 OS RGB -15pins Dsub-15pins PowerPoint PC WindowsXPMicrosoft PowerPoint2002 Microsoft Power Point ( PC ) Windows USB CD-R PC 30 PC PC 36

... 3 CT

CT915 ... 3 CT915... 4... 5... 6... 7... 11... 14... 16... 18... 19... 22... 24... 25... 26... 28... 29... 30... 31 2 3 CT915 120 120 1 1 31 31 4 CT915 s t CR2032 5 1. 2. 5 3. 6 CR2032 CR2032 1. / 1 2.

数学演習：微分方程式

( ) 1 / 21 1 2 3 4 ( ) 2 / 21 x(t)? ẋ + 5x = 0 ( ) 3 / 21 x(t)? ẋ + 5x = 0 x(t) = t 2? ẋ = 2t, ẋ + 5x = 2t + 5t 2 0 ( ) 3 / 21 x(t)? ẋ + 5x = 0 x(t) = t 2? ẋ = 2t, ẋ + 5x = 2t + 5t 2 0 x(t) = sin 5t? ẋ

連携だより34号_201504_034

新センター長挨拶 連携センターからのお知らせ なかつ地域医療連携勉強会 なかつ病院市民講座 部門紹介 入院支援室 診療体制のお知らせ / 新任 退職ドクター紹介 第 34 登録医募集 / 受付時間のご案内 号 2015 年 4 月 CLOSE UP! 診療科 老年内科 社会福祉法人 恩賜 財団 済生会 大阪府済生会中津病院 地域医療連携センター 2015 1 1 11 2 24 12 2 FAX CCU

1

1 6 7 8 9 10 11 12 13 14 15 21:00 22:00 23:00 24:00 18:00 19:00 20:00 16 1 3 ). ). ). 6 ). ). 9 10 12 ). ). 15 ). ). ). 20 ). ). ). 26 2 ). 2 39 3 ). 1. 2. 3. 4. 4 5. 6. ). 5 ). ( ) ( TWITraining

untitled

1 N=14,685 2 3 4 5 6 CT 7 8 9 10 11 540 3female athlete triad) growth spurt,growth rush Cm/ 15 10 5 7 10 15 12 13 Oslo Sports Trauma Center 1992 Bahr,R.Br.J.SportsMed. 2005 ACL ACL ACL ACL a: b: 5 14 15

" " 8 4 5 psyche 8 10 10 12,000 10 24 1 10 7 1 4 1

(This is NOT the actual test.) No.000001 0. ICU 1. 2. 42 (1-42) 3. 90 90 4. 5. 6. 7. 8. 88 Edited by www.bucho-net.com " " 8 4 5 psyche 8 10 10 12,000 10 24 1 10 7 1 4 1 Edited by www.bucho-net.com 1 2

< F2D C8E8691E63395AA8DFB2E6A7464>

1990 CPUE ABC 2-1)ABClimit= 1 Ct 1 =0.6 Cave 1.00 0.8 ABCtarget=ABClimit 0.8 Ct 3 Cave2008 2010 2011 2013ABC ABClimit 170 0.6Cave3-yr1.00 ABCtarget 140 0.80.6Cave3-yr1.00 Cave20082010ABC10 2010 263 2011

M.D.I VDT 29. (1)

5. 5. 5.1 (1 (2 (3 (4 3040 5.2 32 1 1 43 2 44 3 45 13 14 1) 4 45 2 5 46 6 47 7 66 2 8 26 2 1 32 2) 1 2 53 3 39 4 40 5 56 6 29 7 38 8 22 9 22 3 48 2 29 5. 17 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14.

PSCHG000.PS

Interventionalbronchology FA X W G CTM RIAiautopsy im aging Ai Ai P Huganir CT CT RSH HV % % IC U c c c c cc cc cc cc cc c c c c c c c c c c c c c c c c c c c c Hib b Hib H ib H ib PD A IC PD A f

Youth for 3.11 2011

Youth for 3.11 2011 Youth for 3.11 Youth for 3.11 2011 Youth for 3.11 Vision Mission : 1Youth for 3.11 2Youth for 3.11 3Youth for 3.11 Youth for 3.11 Youth for 3.11 Youth for 3.11 Youth for 3.11 Youth

The Lancet NPPV July18, 2009 Non-invasive ventilation in acute respiratory failure ( Review)The Lancet, vol. 374, July 18, 2009 H22.9 The Lancet 2009

The Lancet NPPV July18, 2009 Non-invasive ventilation in acute respiratory failure ( Review)The Lancet, vol. 374, July 18, 2009 H22.9 The Lancet 2009 7 18 NPPV NIV: non-invasive ventilation review NPPV(Non-invasive

45857ebook.pdf

PAP PAP05A1 PAP05A1-F PAP10A1 PAP10A1-F PAP20A PAP20A-F AIR WATER PAP05A1 PAP05A1-F PAP10A1 PAP10A1-F PAP20A PAP20A-F PAP10A1 15

PAP PAP05A1 PAP05A1-F PAP10A1 PAP10A1-F PAP20A PAP20A-F PAP05A1 PAP05A1-F PAP10A1 PAP10A1-F PAP20A PAP20A-F PAP10A1 15 PRECISION PROCESSOR PAPSERIES PAP PAP05A1-W PAP05A1-FW PAP10A1-W PAP10A1-FW PAP20B1-W

表紙/オレンジDIC164　背4.5mm

An overview of regular dialysis treatment in Japan as of Dec. 31, 2004 Japanese Society for Dialysis Therapy An overview of regular dialysis treatment in Japan as of Dec. 31, 2004 Japanese Society for

2

1 2 3 1) 2) 3) 2 3 1 2 3 4 5 6 7 8 9 10 11 4 12 13 14 15 X 16 X 17 X CT 18 MRI 19 20 4 A. ENG T&T B. ABLB SISI ABR ASSRMLRSRL 5 5 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 6 1 2 3 4 7 1 POS( Problem

10K1A NASA () SPACE ATLAS Freedom H2A NASA 1

10O1A 10 10 1 10K1A NASA () SPACE ATLAS 40 1957 1969 10 1986 1990 Freedom 20 000 H2A NASA 1 10K1A 100 10 21 40 1996 ( 200 () 2 10S1A 10 8 57 250 1 10S1A 20 200mmm 2 10S1B 18 18 1 10S1B 40 10 20 2 10S1C

E-mail rsakurai@jade.dti.ne.jp 2000. 2. 1-1-

E-mail rsakurai@jade.dti.ne.jp 2000. 2. 1-1- LD LD LD -2- MBD Minimal Brain Dysfunction Syndrome -3- Minimal Brain Dysfunction Syndrome : --- WISC-WPPSIK-ABC --- CTMRIEEG --- 40 60-4- -5- MBD MBD MBD MBD

山田H17秋セメ.PDF

1 21 2 1 IT 1 2 1 IT IT 2 1980 24 24 3 2005 10 5 4060 309 53 91 87 75 NHK 2 2005 10 10 2004 4 12,007 49,337 6,000 * * * * 500 5 2004 6 12,457 11,636 18.8 15.1 2000 50 9 7 1 100 50 8 3 6 9 1 2 48 2 24.5

Trv1_.xtv

第 0 回 PBF 選手権日本代表選抜試合ウィメン予選 ession 1 01 年 11 月 1 日 ( 土 ) 1 Board (1) - -W Contract L - -W IMP H D H C 0 Board () - -W Contract L - -W IMP H -1 D 0 H -1 D 0 Board () - -W Contract L - -W IMP T -1 D 0 D

< A815B B83578D E9197BF5F906697C38B40945C F92F18B9F91CC90A72E786C73>

がんに対する診療機能 各領域の専門医に加え 認定看護師 専門 認定薬剤師等とともにチーム医療を展開しており 標準的かつ良質 適切な医療の提供に努め 又 他の医療機関との連携を推進しております. 肺がん 当該疾患の診療を担当している 医師数 当該疾患を専門としてい 腫瘍内科 4 4 2 腫瘍外科 ( 外科 ) 5 4 3 腫瘍放射線科 実績実績実績 開胸 治療の実施 (: 実施可 / : 実施不可 )

S E N S O R S September 2016 CCT CCT CCT CCT CCT CCT261631

S E N S O R S September 2016 CCT CCT406393 CCT354571 CCT323047 CCT272440 CCT261631 (2/13) ( ) ( ) ( ) AV (3/13) RoHS CCT RoHS HEMS BEMS FEMS CEMS CCT 406393-600 - 36-00 40 600 600A 36 36mm 63 W 300 300A

20●12頁●６－１４▲放射線科▲.ppt

No.268 Katayama H. et al. Adverse reactions to ionic and nonionic contrast media-a report from the Japanese Committee of the Safety of Contrast Media. Radiology 1990;175:621-628. 12.66% 3.13% 0.22% 0.04%

ニュースレタ-8号最終

QOL IVPCA IVPCAPCA DPC IVPCA PCA IVPCA http://shirobon.net/26/ika_2_11 2018 19 2016 100 2016 40 40 50 60 2014 4 2014 4 6 8 2014 7 2014 2014 7 18 JR a. b. c. 20 100 6 100010 ICU 3 6 C'est la vie hemoglobin

(核)41-1(05)報告33-46

33 Report on Survey of the Adverse Reaction to Radiopharmaceuticals (The 28th Survey in 2002) 6 * Subcommittee of Safety Issue for the Radiopharmaceuticals Medical and Pharmaceutical Committee Japan Radioisotope

天草郡市医師会第139回(臨時)代議員会

A 97 2(B A2) 4(A B3) 2 95 B 104 25(A B3) 16(B A2) 9 113 201 27 20 7 208 2 1 13 3 18 4 19 3 3 2 2 13 4 17 3 18 6 26 6 30 17 18 17 17 17 17 18 ( ) 18 ( ) 18 ( ) 18 ( ) 18 ( ) ( ) ( ) ( ) ( ) ( ) 18 ( ) (

116_0431_0443.doc

1 0Recognized E 60389 Certified LR 20812 PA PAPAFPAL CONNECTOR 2 PAPAPAFPAL CONNECTOR PAPAPAFPAL CONNECTOR 3 1 2 PAPAPAFPAL CONNECTOR 1 2 4 5 PAPA CONNECTOR SPHD-001T-P0.5 SPHD-002T-P0.5 PAP-02V-S PAP-03V-S

116_0431_0443.doc1

1 0Recognized E 60389 Certified LR 20812 PA PAPAFPAL CONNECTOR 2 PAPAPAFPAL CONNECTOR PAPAPAFPAL CONNECTOR 1 2 3 PAPAPAFPAL CONNECTOR 1 2 1 2 4 5 PAPA CONNECTOR SPHD-001T-P0.5 SPHD-002T-P0.5 PAP-02V-S

Title 大動脈解離の高速らせんCT : 腹部大動脈分枝についての検討 Author(s) 早野, 千恵 Journal 東京女子医科大学雑誌, 63(11):1399-1406, 1993 URL http://hdl.handle.net/10470/8839 Twinkle:Tokyo Women's Medical University - http://ir.twmu.ac.jp/dspace/

156 51 1 2015 2 3 6 1 1) 2) 3) 1) 1) 1) 1) 1) 2) 3) 3) 3 1 4 6 2 3 4 Rocky Mountain Soap Rocky Mountain Soap RMS Canmore Banff Pure hand-made 100 toxi

51 1 2015 2 pp. 155-173 155 25 QOL 26 10 18 1993 2000 23 25 3 IT 10 2 end of life living will living will living will 1 NICU QOL NICU QOL 3 6 kg NICU 42 2 kg 2007 NICU 2 NICU/ GCU 25 4 26 3 3 A 156 51

EOS DIGITAL ソフトウェアガイド

EOS DIGITAL EOS Viewer Utility EOS Capture PhotoStitch Windows Macintosh EOS-1D Mark II EOS-1Ds EOS-1D J s Windows Macintosh Windows Windows Macintosh Windows w 1 2 3 4 5 6 7 1 W 1 1 2 3 4 1 2 a 3